Merck & Co. Inc. Initiates Phase 3 HERTHENA-Breast04 Trial for Patritumab Deruxtecan in Treating Advanced HR Positive, HER2 Negative Breast Cancer
I'm PortAI, I can summarize articles.
Merck & Co. Inc. has initiated the HERTHENA-Breast04 phase 3 trial to evaluate the efficacy and safety of patritumab deruxtecan in patients with advanced HR positive, HER2 negative breast cancer. This trial follows promising results from previous studies and aims to provide new treatment options for patients who have not responded to existing therapies. The drug, developed jointly with Daiichi Sankyo, targets HER3 and addresses an unmet medical need in this challenging cancer type. Results from the trial are pending.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments